表紙
市場調査レポート

Ambryx Biotechnology, Inc.の製品パイプライン分析

Ambryx Biotechnology, Inc. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 321983
出版日 ページ情報 英文 16 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
Ambryx Biotechnology, Inc.の製品パイプライン分析 Ambryx Biotechnology, Inc. - Product Pipeline Review - 2015
出版日: 2015年04月15日 ページ情報: 英文 16 Pages
概要

Ambryx Biotechnology, Inc.は米国に本社をもつファーマシューティカル企業であり、抗癌剤や癌患者向け栄養製品の開発・販売の他、癌治療用のミルクペプチド分離・活性化技術の開発などを行っています。

当レポートでは、Ambryx Biotechnology, Inc.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

Ambryx Biotechnology, Inc.の基本情報

  • Ambryx Biotechnology, Inc.の概要
  • 主要情報
  • 企業情報

Ambryx Biotechnology, Inc.:R&Dの概要

  • 主な治療範囲

Ambryx Biotechnology, Inc.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Ambryx Biotechnology, Inc.:パイプライン製品の概況

  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ

Ambryx Biotechnology, Inc.:薬剤プロファイル

  • CR-27303
  • CR-58242
  • CR-66357

Ambryx Biotechnology, Inc.:パイプライン分析

  • 分子タイプ別

Ambryx Biotechnology, Inc.:本社と子会社の所在地

  • 本社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC06944CDB

Summary

Global Markets Direct's, 'Ambryx Biotechnology, Inc. - Product Pipeline Review - 2015', provides an overview of the Ambryx Biotechnology, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Ambryx Biotechnology, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Ambryx Biotechnology, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Ambryx Biotechnology, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Ambryx Biotechnology, Inc.'s pipeline products

Reasons to buy

  • Evaluate Ambryx Biotechnology, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Ambryx Biotechnology, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Ambryx Biotechnology, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Ambryx Biotechnology, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Ambryx Biotechnology, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Ambryx Biotechnology, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Ambryx Biotechnology, Inc. Snapshot
    • Ambryx Biotechnology, Inc. Overview
    • Key Information
    • Key Facts
  • Ambryx Biotechnology, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Ambryx Biotechnology, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Ambryx Biotechnology, Inc. - Pipeline Products Glance
    • Ambryx Biotechnology, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Ambryx Biotechnology, Inc. - Drug Profiles
    • CR-27303
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CR-58242
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CR-66357
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Ambryx Biotechnology, Inc. - Pipeline Analysis
  • Ambryx Biotechnology, Inc. - Pipeline Products by Molecule Type
  • Ambryx Biotechnology, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Ambryx Biotechnology, Inc., Key Information
  • Ambryx Biotechnology, Inc., Key Facts
  • Ambryx Biotechnology, Inc. - Pipeline by Indication, 2015
  • Ambryx Biotechnology, Inc. - Pipeline by Stage of Development, 2015
  • Ambryx Biotechnology, Inc. - Monotherapy Products in Pipeline, 2015
  • Ambryx Biotechnology, Inc. - Preclinical, 2015
  • Ambryx Biotechnology, Inc. - Pipeline by Molecule Type, 2015

List of Figures

  • Ambryx Biotechnology, Inc. - Pipeline by Top 10 Indication, 2015
Back to Top